S212: PHASE I STUDY OF YTB323, A CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELL THERAPY MANUFACTURED USING T-CHARGE™, IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA. (23rd June 2022) - Dickinson, M.; Kwon, M.; Briones, J.; Jäger, U.; Kato, K.; Bachy, E.; Blaise, D.; Boissel, N.; Shah, N.; Frigault, M; Riedell, P.; Shune, L.; et al.